Literature DB >> 8458321

The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.

J M Slingerland1, J R Jenkins, S Benchimol.   

Abstract

Mutant p53 alleles that have a recessive phenotype in human tumors can, in cooperation with an activated H-ras gene, transform rat embryo fibroblasts (REFs). Mutant p53 proteins differ from wild type, and from each other in conformation, localization and transforming potential. Missense mutations in codons 143, 175 and 275 confer strong transforming potential. A serine 135 p53 mutant has an intermediate transforming potential, while the histidine codon 273 allele transforms weakly, if at all. In contrast to the wild type p53 gene, mutant p53 alleles with strong transforming ability cannot suppress the transformation of REFs by other oncogenes. The His273 allele retains partial suppressor function in this assay. The relevance of p53 oligomerization, phosphorylation and nuclear translocation to the transforming potential of mutant p53 and to wild type p53 suppressor function were examined. The inability of mutant p53 polypeptides to form homodimers correlates with loss of transforming function. Monomeric variants of wild type p53 protein, however, retain the ability to suppress focus formation. Phosphorylation of serine residues 315 and 392 is not required for the transforming function of mutant p53, nor is serine 315 required for suppressor function when these alleles are constitutively expressed in REF assays. Nuclear translocation-defective mutant and wild type p53 proteins retain transforming and suppressor function in REF assays.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458321      PMCID: PMC413304          DOI: 10.1002/j.1460-2075.1993.tb05744.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  65 in total

1.  A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.

Authors:  H W Stürzbecher; R Brain; C Addison; K Rudge; M Remm; M Grimaldi; E Keenan; J R Jenkins
Journal:  Oncogene       Date:  1992-08       Impact factor: 9.867

2.  Nuclear localization is essential for the activity of p53 protein.

Authors:  G Shaulsky; N Goldfinger; M S Tosky; A J Levine; V Rotter
Journal:  Oncogene       Date:  1991-11       Impact factor: 9.867

Review 3.  p53: oncogene or anti-oncogene?

Authors:  D P Lane; S Benchimol
Journal:  Genes Dev       Date:  1990-01       Impact factor: 11.361

4.  The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif.

Authors:  C Addison; J R Jenkins; H W Stürzbecher
Journal:  Oncogene       Date:  1990-03       Impact factor: 9.867

5.  Phosphorylation of large tumour antigen by cdc2 stimulates SV40 DNA replication.

Authors:  D McVey; L Brizuela; I Mohr; D R Marshak; Y Gluzman; D Beach
Journal:  Nature       Date:  1989-10-12       Impact factor: 49.962

Review 6.  RB and the cell cycle: entrance or exit?

Authors:  J A Cooper; P Whyte
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

7.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

8.  Wild-type p53 can inhibit oncogene-mediated focus formation.

Authors:  D Eliyahu; D Michalovitz; S Eliyahu; O Pinhasi-Kimhi; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  p53: a frequent target for genetic abnormalities in lung cancer.

Authors:  T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

10.  Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins.

Authors:  C V Dang; W M Lee
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

View more
  21 in total

1.  Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding.

Authors:  F Janus; N Albrechtsen; U Knippschild; L Wiesmüller; F Grosse; W Deppert
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

2.  The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells.

Authors:  N Almog; R Li; A Peled; D Schwartz; R Wolkowicz; N Goldfinger; H Pei; V Rotter
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

3.  p53 is an important regulator of CCL2 gene expression.

Authors:  X Tang; M Asano; A O'Reilly; A Farquhar; Y Yang; S Amar
Journal:  Curr Mol Med       Date:  2012-09       Impact factor: 2.222

4.  Atomic force microscopy visualizes ATP-dependent dissociation of multimeric TATA-binding protein before translocation into the cell nucleus.

Authors:  H Oberleithner; S Schneider; J O Bustamante
Journal:  Pflugers Arch       Date:  1996-09       Impact factor: 3.657

5.  Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form.

Authors:  R Wolkowicz; A Peled; N B Elkind; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

6.  Interaction of p53 with its consensus DNA-binding site.

Authors:  Y Wang; J F Schwedes; D Parks; K Mann; P Tegtmeyer
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

7.  p53 domains: structure, oligomerization, and transformation.

Authors:  P Wang; M Reed; Y Wang; G Mayr; J E Stenger; M E Anderson; J F Schwedes; P Tegtmeyer
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

8.  p53 suppresses CCL2-induced subcutaneous tumor xenograft.

Authors:  Xiaoren Tang; Salomon Amar
Journal:  Tumour Biol       Date:  2014-12-11

Review 9.  Familial breast cancer and genes involved in breast carcinogenesis.

Authors:  A Lindblom
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

10.  Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle.

Authors:  Y Chen; P L Chen; W H Lee
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.